Could albumin boost oxygen delivery in sepsis? new trial investigates

NCT ID NCT06556914

Completed Disease control Sponsor: Samsun University Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial tests whether replacing albumin—a protein in the blood—can improve oxygen delivery in sepsis patients in the intensive care unit. Sepsis is a life-threatening response to infection that can starve organs of oxygen. The study includes adults with sepsis and low albumin levels who have already received standard fluid therapy. Researchers will measure oxygen delivery and track changes in organ function to see if albumin offers an added benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: albumin
What this could lead to: If it works, this could point toward a better fluid therapy strategy for sepsis patients in intensive care, potentially improving oxygen delivery and organ function.
What could go wrong: This is a small, early-stage study with only 45 participants, so results may not be conclusive or generalizable. Albumin replacement carries risks like allergic reactions or fluid overload.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTENSIVE CARE UNIT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTENSIVE CARE UNIT SEPSIS

Contacts and locations

Show contact details

Locations

Samsun University

Samsun, Ilkadım, 55100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.